) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015) declined by about 1.5% annually in both men and women. The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak. Of the 10 leading causes of death, only cancer declined from 2014 to 2015. In 2015, the cancer death rate was 14% higher in non-Hispanic blacks (NHBs) than non-Hispanic whites (NHWs) overall (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13-1.15), but the racial disparity was much larger for individuals aged <65 years (DRR, 1.31; 95% CI, 1.29-1.32) compared with those aged 65 years (DRR, 1.07; 95% CI, 1.06-1.09) and varied substantially by state. For example, the cancer death rate was lower in NHBs than NHWs in Massachusetts for all ages and in New York for individuals aged 65 years, whereas for those aged <65 years, it was 3 times higher in NHBs in the District of Columbia (DRR, 2.89; 95% CI, 2.16-3.91) and about 50% higher in Wisconsin (DRR, 1.78; 95% CI, 1.56-2.02), Kansas (DRR, 1.51; 95% CI, 1.25-1.81), Louisiana (DRR, 1.49; 95% CI, 1.38-1.60), Illinois (DRR, 1.48; 95% CI, 1.39-1.57), and California (DRR, 1.45; 95% CI, 1.38-1.54). Larger racial inequalities in young and middle-aged adults probably partly reflect less access to high-quality health care. CA Cancer J Clin 2018;68:7-30.
Introduction
Cancer is a major public health problem worldwide and is the second leading cause of death in the United States. In this article, we provide the estimated numbers of new cancer cases and deaths in 2018 in the United States nationally and for each state, as well as a comprehensive overview of cancer occurrence based on the most current population-based data for cancer incidence through 2014 and for mortality through 2015. We also estimate the total number of deaths averted as a result of the continual decline in cancer death rates since the early 1990s and quantify the black-white disparity in cancer mortality by state and age based on the actual number of reported cancer deaths in 2015.
Materials and Methods

Incidence and Mortality Data
Mortality data from 1930 to 2015 were provided by the National Center for Health Statistics (NCHS). [1] [2] [3] Forty-seven states and the District of Columbia (DC) met data quality requirements for reporting to the national vital statistics system in 1930. Texas, Alaska, and Hawaii began reporting mortality data in 1933, 1959, and 8,730  370  4,510  2,330  1,820  8,780  2,890  2,590  5,400  3,070  Minnesota  31,270  4,500  140  2,270  1,120  1,270  3,980  1,420  1,420  2,920  1,380  Mississippi  18,130  2,240  150  1,550  430  560  2,690  590  560  1,370  620  Missouri  35,520  5,160  250  2,890  1,240  1,240  5,750  1,800  1,480  3,000  1,640  Montana  6,080  1,020   †  520  220  230  830  440  280  810  350  Nebraska  10,320  1,560  70  900  380  410  1,310  540  460  960  490  Nevada  14,060  2,180  130  1,130  410  500  2,090  790  580  1,190  770  New Hampshire  8,080  1,360   †  590  360  280  1,230  460  370  840  520  New Jersey  53,260  8,550  380  4,100  2,180  1,990  5,870  2,830  2,370  5,430  2,590  New Mexico  9,730  1,470  80  800  340  360  1,090  500  410  960  390  New York  110,800  17,890  870  9,080  4,580  4,410  13,190  4,920  4,890  9,880  5,440  North Carolina  55,130  7,760  410  4,440  1,910  2,050  8,490  3,310  2,240  5,580  2,530  North Dakota  4,110  570   †  350  140  150  500  220  170  380  200  Ohio  68,470  10,610  480  5,550  2,740  2,060  10,760  3,400  2,880  5,810  3,350  Oklahoma  19,030  2,870  170  1,670  590  710  3,210  860  860  1,670  890  Oregon  21,520  3,400  140  1,510  890  650  3,140  1,570  1,010  2,040  1,130  Pennsylvania  80,960  12,140  500  6,440  3,320  2,930  10,470  4,320  3,430  7,360  4,240  Rhode Island  5,920  1,010   †  460  260  190  880  280  270  740  360  South Carolina  30,450  4,540  220  2,410  920  960  4,630  1,820  1,150  3,080  1,310  South Dakota  5,100  740   †  440  170  190  650  270  220  510  260  Tennessee  36,760  5,590  310  3,110  1,130  1,370  6,030  1,900  1,540  2,750  1,660  Texas  121,860  18,260  1,360  10,080  4,000  4,580  15,460  4,440  5,460  12,600  4,530  Utah  10,950  1,720  70  780  400  480  900  1,010  520  1,250  440  Vermont  3,840  600   †  270  160  120  560  230  170  390  250  Virginia  42,420  7,510  290  3,380  1,570  1,250  5,860  2,620  1,760  4,200  1,900  Washington  36,170  5,580  240  2,710  1,390  1,330  4,810  2,650  1,770  3,730  1,940  West Virginia  12,110  1,700  90  1,030  450  390  2,060  720  480  820  620  Wisconsin  33,340  5,420  190  2,650  1,410  1,350  4,400  1,740  1,410  3,660  1,710  Wyoming  2,780  450   †  210  100  100  330  200  120  330  160  United States  1,735,350 266,120 13,240 140,250 63,230  60,300  234,030  91,270  74,680  164,690 81,190 *Rounded to the nearest 10; excludes basal cell and squamous cell skin cancers and in situ carcinomas except urinary bladder. †Estimate is fewer than 50 cases.
Note: These are model-based estimates that should be interpreted with caution and not compared to those for previous years. State estimates may not add to US total due to rounding and the exclusion of states with fewer than 50 cases.
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1960, respectively. The methods for abstraction and age adjustment of mortality data are described elsewhere. 3, 4 Population-based cancer incidence data in the United States have been collected by the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) Program since 1973 and by the Centers for Disease Control and Prevention's (CDC's) National Program of Cancer Registries (NPCR) since 1995. The SEER program is the only source for historic population-based incidence data. Long-term incidence and survival trends were based on data from the 9 oldest SEER areas (Connecticut, Hawaii, Iowa, New Mexico, Utah, and the metropolitan areas of Atlanta, Detroit, San Francisco-Oakland, and Seattle-Puget Sound), representing approximately 9% of the US population. 5 The lifetime probability of developing cancer and contemporary stage distribution and survival statistics were based on data from all 18 SEER registries (the SEER 9 registries plus Alaska Natives, California, Georgia, Kentucky, Louisiana, and New Jersey), covering 28% of the US population. 6 The probability of developing cancer was calculated using NCI's DevCan software (version 6.7.5). 7 Some of the statistical information presented herein was adapted from data previously published in the SEER Cancer Statistics Review 1975-2014. The North American Association of Central Cancer Registries (NAACCR) compiles and reports incidence data from 1995 onward for registries that participate in the SEER program and/or the NPCR. These data approach 100% coverage of the US population in the most recent time period and were the source for the projected new cancer cases in 2018 and cross-sectional incidence rates by state and race/ethnicity. 9,10 Some of the incidence data presented herein were previously published in volumes 1 and 2 of Cancer in North America: 2010-2014.
11,12
All cancer cases were classified according to the International Classification of Diseases for Oncology except childhood and adolescent cancers, which were classified according to the International Classification of Childhood Cancer (ICCC). 13, 14 Causes of death were classified according to the International Classification of Diseases. 15 All incidence and death rates were age-standardized to the 2000 US standard population and expressed per 100,000 population, as calculated by NCI's SEER*Stat software (version 8.3.4). 16 The annual percent change in rates was quantified using NCI's Joinpoint Regression Program (version 4.5.0.1).
17
Whenever possible, cancer incidence rates presented in this report were adjusted for delays in reporting, which occur because of a lag in case capture or data corrections. Delay adjustment has the largest effect on the most recent years of data for cancers that are frequently diagnosed in outpatient settings (eg, melanoma, leukemia, and prostate cancer) and provides a more accurate portrayal of the cancer burden in the most recent time period. 18 For example, the leukemia incidence rate for 2014 is 13% higher after adjusting for reporting delays. 19 
Projected Cancer Cases and Deaths in 2018
The most recent year for which reported incidence and mortality data are available lags 2 to 4 years behind the current Cancer Statistics, 2018 year due to the time required for data collection, compilation, quality control, and dissemination. Therefore, we projected the numbers of new cancer cases and deaths in the United States in 2018 to provide an estimate of the contemporary cancer burden.
To calculate the number of invasive cancer cases, a generalized linear mixed model was used to estimate complete counts for each county (or health service area for rare cancers) from 2000 through 2014 using high-quality incidence data from 48 states and DC (approximately 96% population coverage) and geographic variations in sociodemographic and lifestyle factors, medical settings, and cancer screening behaviors. 20 Data were unavailable for all years for Kansas and Minnesota and for some years for other states. Modeled counts were adjusted for delays in cancer reporting using registry-specific or combined delay ratios and aggregated to obtain national-and state-level counts for each year. Finally, a time series projection method (vector autoregression) was applied to all 15 years of modeled data to estimate counts for 2018. This method cannot estimate numbers of basal cell or squamous cell skin cancers because data on the occurrence of these cancers are generally not reported to cancer registries. For complete details of the case projection methodology, please refer to Zhu et al. 21 In situ cases of female breast carcinoma and melanoma of the skin diagnosed in 2018 were estimated by first approximating the number of cases occurring annually from 2005 through 2014 based on age-specific NAACCR incidence rates (data from 46 states and DC with high-quality data every year) and US population estimates provided in SEER*-Stat. Counts were then adjusted for delays in reporting using SEER delay factors for invasive breast cancer and melanoma, respectively, because delay factors are not available for in situ cases. Counts were then projected to 2018 based on the average annual percent change during the entire time period as generated by the joinpoint regression model. Note: These are model-based estimates that should be interpreted with caution and not compared to those for previous years. State estimates may not add to US total due to rounding and the exclusion of states with fewer than 50 deaths.
The number of cancer deaths expected to occur in 2018 was estimated based on the most recent joinpoint-generated annual percent change in reported cancer deaths from 2001 through 2015 at the state and national levels as reported to the NCHS. For the complete details of this methodology, please refer to Chen et al. 22 
Other Statistics
The number of cancer deaths averted in men and women due to the reduction in cancer death rates since the early 1990s was estimated by summing the difference between the annual number of recorded cancer deaths from the number that would have been expected if cancer death rates had remained at their peak. The expected number of deaths was estimated by applying the 5-year age-and sex-specific cancer death rates in the peak year for age-standardized cancer death rates (1990 in men and 1991 in women) to the corresponding age-and sex-specific populations in subsequent years through 2015. We also calculated the racial disparity in overall cancer mortality by state and age (<65 years and 65 years) in 2015 based on death rate ratios (DRRs) comparing non-Hispanic blacks (NHBs) with non-Hispanic whites (NHWs) using SEER*Stat. Figure 1 depicts the most common cancers expected to occur in men and women in 2018. Prostate, lung and bronchus (referred to as lung hereafter), and colorectal cancers account for 42% of all cases in men, with prostate cancer alone accounting for almost 1 in 5 new diagnoses. For women, the 3 most common cancers are breast, lung, and colorectum, which collectively represent one-half of all cases; breast cancer alone accounts for 30% all new cancer diagnoses in women.
Selected Findings Expected Numbers of New Cancer Cases
The lifetime probability of being diagnosed with invasive cancer is slightly higher for men (39.7%) than for women (37.6%) ( Table 3 ). The reasons for the increased susceptibility in men are not well understood, but to some extent reflect differences in environmental exposures, endogenous hormones, and probably complex interactions between these influences. Adult height, which is determined by genetics and childhood nutrition, is positively associated with cancer incidence and death in both men and women, 23 and has been estimated to account for one-third of the sex disparity. 24 
Expected Numbers of Cancer Deaths
An estimated 609,640 Americans will die from cancer in 2018, corresponding to almost 1,700 deaths per day (Table 1 ). The most common causes of cancer death are cancers of the lung, prostate, and colorectum in men and the lung, breast, and colorectum in women ( Fig. 1 ). These 4 cancers account for 45% of all cancer deaths, with one-quarter due to lung cancer. Table 4 provides the estimated numbers of cancer deaths in 2018 by state for selected cancers. Figure 2 illustrates long-term trends in cancer incidence rates for all cancers combined by sex. Cancer incidence patterns reflect trends in behaviors associated with cancer risk and changes in medical practice, such as the use of cancer screening tests. The volatility in incidence for males compared with females reflects rapid changes in prostate cancer incidence, which spiked in the late 1980s and early 1990s ( Fig. 3 ) due to a surge in the detection of asymptomatic disease as a result of widespread prostate-specific antigen (PSA) testing. 25 Over the past decade of data, the overall cancer incidence rate in men declined by about 2% per year, with the pace accelerating in more recent years (Table 5 ). This trend reflects large continuing declines for cancers of the lung and colorectum, in addition to a sharp reduction in prostate cancer incidence of about 10% annually from 2010 to 2014. The drop in prostate cancer incidence has been attributed to 26, 27 The effect of screening reductions on the incidence of advanced disease is being monitored closely. One analysis of SEER data through 2012 indicated a slight uptick in the diagnosis of distant stage prostate cancer among men aged 50 to 69 years, 28 which may reflect the larger downturn in PSA testing among younger men. 29, 30 In April 2017, the Task Force issued a draft statement revising its recommendation for men aged 55 to 69 years to informed decision making (Grade C) based on an updated evidence review. 31, 32 The overall cancer incidence rate in women has remained generally stable over the past few decades because declines in lung and colorectal cancers have been offset by increasing or stable rates for breast, uterine corpus, and thyroid cancers and for melanoma ( Table 5 ). The slight increase in breast cancer incidence from 2005 to 2014 was driven by increases of 0.3% to 0.4% per year among Hispanic and black women and 1.7% per year among Asian/Pacific Islander women; rates among NHWs and American Indians/Alaska Natives remained stable. 33 Lung cancer incidence rates continue to decline about twice as fast in men as in women, reflecting historical differences in tobacco uptake and cessation, as well as upturns in female smoking prevalence in some birth cohorts. 34, 35 In contrast, colorectal cancer (CRC) incidence patterns are generally similar in men and women (Fig. 3) ; from 2005 through 2014, incidence rates declined annually by about 2% to 3%, although the trend may have stabilized in women during the most recent data years (Table 5) . Reductions in CRC incidence prior to 2000 are attributed equally to changes in risk factors and the use of screening, which allows for the removal of premalignant lesions. 36 However, more recent rapid declines are thought to primarily reflect increased uptake of colonoscopy, which now is the predominant screening test. 37, 38 Colonoscopy use among US adults aged 50 years and older tripled from 21% in 2000 to 60% in 2015.
Trends in Cancer Incidence
39 In contrast to the rapid declines in CRC incidence overall, which are driven by trends in older age groups, rates in individuals aged younger than 55 years increased by almost 2% per year from the mid-1990s to 2014. 40 Liver cancer incidence continues to increase rapidly in women, but appears to be plateauing in men since 2010 (Table 5) . However, trends vary by age; from 2010 to 2014, rates increased annually by 1% to 2% in men and women aged younger than 40 years, decreased or were stable in men and women aged 40 to 59 years, and increased annually by 8% in individuals aged 60 to 69 years and by 3% in those aged 70 years and older. 40 There is potential to avert much of the future burden of liver cancer associated with hepatitis C virus (HCV) infection through increased HCV detection coupled with new, well-tolerated antiviral therapies that lower the risk of hepatocellular carcinoma. 41, 42 Most HCV-infected individuals are undiagnosed, and 80% are baby boomers (those born between 1945 and 1965), for whom one-time screening has been recommended since 2012. 43, 44 Several states have even mandated that health care providers offer HCV testing to appropriate patients. 45 However, of the Rates are age adjusted to the 2000 US standard population. Due to improvements in International Classification of Diseases (ICD) coding over time, numerator data for cancers of the lung and bronchus, colon and rectum, liver, and uterus differ from the contemporary time period. For example, rates for lung and bronchus include pleura, trachea, mediastinum, and other respiratory organs.
more than 76 million estimated baby boomers in 2015, only 14% reported having received HCV testing. 46 Adding to the disease burden is a worrisome 2-fold increase in HCV infections from 2010 to 2014 (following a stable trend) driven by individuals aged 20-39 years as a consequence of the opioid epidemic. The long-term, rapid rise in melanoma incidence appears to be slowing, particularly among younger age groups; from 2005 to 2014, rates were stable in men and women aged younger than 50 years (except for declines of 0.7% annually in men aged 40-49 years), while increasing more rapidly with advancing age in those aged 50 years and older. Incidence rates for thyroid cancer also may have begun to stabilize in recent years, particularly among whites, 8 in the wake of changes in clinical practice guidelines that include more conservative indications for biopsy and the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. [47] [48] [49] HIV indicates human immunodeficiency virus.
*Includes primary and secondary hypertension.
Note: Deaths within each age group do not sum to all ages combined due to the inclusion of unknown ages. In accordance with the National Center for Health Statistics' cause-of-death ranking, "Symptoms, signs, and abnormal clinical or laboratory findings" and categories that begin with "Other" and "All other" were not ranked. 
Cancer Survival
For all cancers combined, the 5-year relative survival rate is 68% in whites and 61% in blacks. 8 Figure 4 shows 5-year relative survival rates by cancer type and race during the most recent time period (2007) (2008) (2009) (2010) (2011) (2012) (2013) . For all stages combined, survival is highest for prostate cancer (99%), melanoma of the skin (92%), and female breast cancer (90%) and lowest for cancers of the pancreas (8%), lung (18%), and liver (18%). Survival is lower for black than for white patients for every cancer type shown in Figure 4 except cancers of the kidney and pancreas, with an absolute difference 10% for more than one-half of these. The largest differences are for melanoma (26%) and cancers of the uterine corpus (22%) and oral cavity and pharynx (18%), in part reflecting a much later stage at diagnosis in black patients (Fig. 5) . Blacks are more likely than whites to be diagnosed with cancer at an advanced stage, but also have lower stage-specific survival for most cancer types. After adjusting for sex, age, and stage at diagnosis, the relative risk of death after a cancer diagnosis is 33% higher in black patients than in white patients. 50 The disparity is even more striking for American Indians/Alaska Natives, who are 51% more likely than whites to die from their cancer. Cancer survival has improved since the mid-1970s for all of the most common cancers except those of the uterine cervix and uterine corpus, 50 although increased survival for some cancer types (eg, breast and prostate) is difficult to interpret because of changes in detection practice (eg, lead time bias). Progress has been especially rapid for hematopoietic and lymphoid malignancies due to improvements in treatment protocols, including the discovery of targeted therapies. For example, the 5-year relative survival rate for chronic myeloid leukemia increased from 22% for patients diagnosed in the mid-1970s to 68% for those diagnosed during 2007 through 2013. 8 Based on a review of clinical trial data, most patients with chronic myeloid leukemia who are treated with tyrosine kinase inhibitors experience near normal life expectancy, particularly those diagnosed before age 65 years. 51 In general, oncology advances have benefitted patients aged 50 to 64 years more than their older counterparts, likely reflecting lower efficacy or use of new therapies in the elderly population. 52 Survival gains are also often stage specific; for example, patients with liver cancer diagnosed at a localized stage had among the largest absolute gains in survival over the past 3 decades, largely because of advances in liver transplantation, whereas those diagnosed with distant stage disease had no improvement. 50 In contrast to the steady increase in survival observed for most cancer types, advances have been slow for lung and pancreatic cancers, which are typically diagnosed at a distant stage (Fig. 5) , for which the 5-year survival rates are 5% and 3%, respectively. There is potential for lung cancer to be diagnosed at an earlier stage among high-risk individuals through the use of screening with low-dose computed tomography (LDCT), which has been shown to reduce lung cancer mortality by up to 20% among current and former smokers with a smoking history of 30 or more packyears.
53, 54 However, in 2015, only 4% of the 6.8 million Cancer Statistics, 2018 eligible Americans reported being screened for lung cancer with LDCT. 55 
Trends in Cancer Mortality
Mortality trends are the best indicator of progress against cancer because they are less affected by detection practices than incidence and survival. 56 The overall cancer death rate rose during most of the 20th century, largely driven by rapid increases in lung cancer deaths among men as a consequence of the tobacco epidemic, but has declined by about 1.5% per year since the early 1990s. From its peak of 215.1 (per 100,000 population) in 1991, the cancer death rate dropped 26% to 158.6 in 2015. This decline, which is larger in men (32% since 1990) than in women (23% since 1991), translates to approximately 2,378,600 fewer cancer deaths (1,639,100 in men and 739,500 in women) than what would have occurred if peak rates had persisted (Fig. 6) . The decline in cancer mortality over the past 2 decades is primarily the result of steady reductions in smoking and advances in early detection and treatment, reflected in considerable decreases for the 4 major cancers (lung, breast, prostate, and colorectum) (Fig. 7) . Specifically, the death rate dropped CI indicates confidence interval; DRR, death rate ratio; NHB, non-Hispanic black; NHW, non-Hispanic white.
States with 50 cancer deaths among NHB individuals.*Based on data from the 5-year American Community Survey, 2011-2015.
Gray shading indicates that the death rate for NHB individuals is statistically significantly higher than that for NHW individuals.
No shading indicates that there is no statistical difference between the death rate for NHB and NHW individuals.
Blue shading indicates that the death rate for NHB individuals is statistically significantly lower than that for NHW individuals.
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*This state's data are not included in the US combined rates because they did not consent (Kansas) or because they did not meet high-quality standards for one or more years during 2010 to 2014 according to the North American Association of Central Cancer Registries (NAACCR). †Rates are based on incidence data for 2008 to 2010. ‡Rates are based on incidence data for 2010 to 2012.
Cancer Statistics, 2018 57 The rapid declines in prostate cancer mortality, attributed to earlier detection due to PSA testing and advances in treatment, 58 appear to be plateauing in recent years in men aged younger than 70 years. 1 Similarly, CRC death rates increased slightly in individuals aged younger than 55 years since the mid2000s, 59 despite rapid declines in older age groups.
In contrast to the overall declining trends for the 4 major cancers, death rates rose during 2011 through 2015 for liver cancer by 2.7% per year in women and by 1.6% per year in men, as well as for uterine corpus cancer by about 2% per year and for pancreatic cancer in men by 0.3% per year (Table 6 ). Death rates also increased slightly for cancers of the brain and other nervous system in both sexes and the oral cavity and pharynx in men. 1 
Recorded Number of Deaths in 2015
A total of 2,712,630 deaths were recorded in the United States in 2015, 22% of which were from cancer ( Table 7) . Of the 10 leading causes of death, cancer was the only one for which the age-standardized death rate declined from 2014 to 2015 (by 1.7%). 60 Cancer is the second leading cause of death after heart disease in both men and women nationally, but is the leading cause of death in many states 61 and in Hispanic and Asian Americans. 62, 63 Cancer is the first or second leading cause of death for every age group shown in Table  8 among females, whereas accidents, assault, and suicide predominate among males aged younger than 40 years. Table 9 presents the number of deaths in 2015 for the 5 leading cancer types by age and sex. Among men, the leading cause of cancer death is brain and other nervous system tumors before age 40 years and lung cancer in those of older ages. Among women, the leading cause of cancer death is brain and other nervous system tumors before age 20 years, breast cancer from ages 20 to 59 years, and lung cancer thereafter. Notably, cervical cancer is the second leading cause of cancer death in women aged 20 to 39 years, underscoring the need for increased screening in young women, as well higher uptake of the human papillomavirus (HPV) vaccination. In 2016, only one-half (49.5%) of females aged 13 to 17 years were up to date with HPV vaccination. 64 
Cancer Disparities by Race/Ethnicity
Cancer occurrence and outcomes vary considerably between racial and ethnic groups, largely because of inequalities in wealth that lead to differences in risk factor exposures and barriers to high-quality cancer prevention, early detection, and treatment. 65, 66 Cancer incidence and mortality are generally highest among NHBs and lowest among Asian/ Pacific Islanders (Table 10 ). The overall cancer incidence rate in NHB men is 85% higher than that in Asian/Pacific Islander men and 10% higher than that in NHW men, although rates are higher in NHWs compared with NHBs for men aged younger than 45 years and older than 80 years. Notably, NHB women have 7% lower cancer incidence than NHW women because of lower rates of breast and lung cancer, but 14% higher overall cancer mortality.
In men and women combined, the cancer death rate in 2015 was 14% higher in NHBs than in NHWs (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13-1.15), down from a peak of 33% in 1993. However, the racial gap was substantially larger for individuals aged younger than 65 years (DRR, 1.31; 95% CI, 1.29-1.32) than for those aged 65 years or older (DRR, 1.07; 95% CI, 1.06-1.09), probably in part due to universal health care access for seniors through Medicare. Racial inequalities have also been shown to vary substantially across states. 33 Among the 40 states (including DC) for which there was a sufficient number (50) of cancer deaths in NHBs for stable estimates, the DRR in blacks Some of the variation in racial disparities by state may reflect the growing number of black immigrants, who are healthier and older than their native-born counterparts, and now account for 9% of the US black population. The number of foreign-born blacks more than doubled over the past 2 decades, from 1.4 million in 1990 to 3.8 million in 2013, and is highly concentrated in the Northeast and the South. 67 The proportion of the black population that was foreign born in 2011-2015 was 28% in 10 states, including New York (28%) and Massachusetts (34%) ( Table 11 ). Immigrant populations have lower disease rates than those born in the United States, partly because of more favorable characteristics such as lower smoking and obesity prevalence. [68] [69] [70] One study found that foreign-born blacks in the United States have cancer mortality rates that are about 10% lower than those of native NHWs and 40% lower than those of native blacks. 68 Comprehensive health care reform in Massachusetts, which began rolling out in 2006 and has achieved near-universal insurance coverage, has been associated with mortality reductions 71 and may have also contributed to the state's success in eliminating racial disparities. Tables 12 and 13 show cancer incidence and mortality rates for selected cancers by state. State variation in cancer incidence results from differences in medical detection practice and the prevalence of risk factors, such as smoking, obesity, and other health behaviors. For example, the large geographic variation in HPV vaccination coverage, which ranged from 29% in Mississippi and South Carolina to 71% in Rhode Island in 2016, 64 may contribute to future differential patterns in HPV-associated cancers. 72, 73 Geographic disparities, which have increased over time, 74, 75 often reflect the national distribution of poverty. This trend may be exacerbated by widening inequalities in access to health care because of state differences in Medicaid expansion and other initiatives to improve insurance coverage. 76, 77 The largest geographic variation in cancer occurrence by far is for lung cancer, reflecting the large historical and continuing differences in smoking prevalence between states. 57 For example, lung cancer incidence rates in Kentucky (116 per 100,000 population in men and 80 per 100,000 population in women), where smoking prevalence continues to be highest, are about 3.5 times higher than those in Utah (33 per 100,000 population in men and 24 per 100,000 population in women), where smoking prevalence is lowest. In 2015, more than one-quarter (26%) of residents in Kentucky and West Virginia were current smokers compared with 9% in Utah. 78 Smoking history similarly predicts state disparities in smoking-attributable mortality; the proportion of total cancer deaths caused by smoking in 2014 was 38% in men and 29% in women in Kentucky, compared with 22% and 11%, respectively, in Utah.
Geographic Variation in Cancer Occurrence
Cancer in Children and Adolescents
Cancer is the second most common cause of death among children aged 1 to 14 years in the United States, surpassed only by accidents. In 2018, an estimated 10,590 children (birth to 14 years) will be diagnosed with cancer (excluding benign/borderline malignant brain tumors) and 1,180 will die from the disease. Benign and borderline malignant brain tumors are not included in the 2018 case estimates because the calculation method requires historical data and these tumors were not required to be reported to cancer registries until 2004.
Leukemia accounts for 29% of all childhood cancers (including benign and borderline malignant brain tumors), threequarters of which are lymphoid. Brain and other nervous system tumors are second most common (26%), of which approximately one-quarter are benign/borderline malignant. The third most common category is lymphomas and reticuloendothelial neoplasms (12%), almost one-half of which are nonHodgkin lymphoma (including Burkitt lymphoma) and one-quarter of which are Hodgkin lymphoma. Soft tissue sarcomas (almost one-half of which are rhabdomyosarcoma) and neuroblastoma each account for 6% of childhood cancers, followed by renal (Wilms) tumors (5%). 9 Cancers in adolescents (aged 15 to 19 years) differ somewhat from those in children in terms of type and distribution. For example, brain and other nervous system tumors (21%) (more than one-half [58%] of which are benign/borderline malignant) and lymphoma (20%) are equally common, and there are almost twice as many cases of Hodgkin lymphoma as non-Hodgkin lymphoma. Leukemia is third (13%), followed by germ cell and gonadal tumors (11%) and thyroid carcinoma (11%). Melanoma of the skin accounts for 4% of the cancers diagnosed in adolescents.
Although overall cancer incidence in children and adolescents has been increasing slightly (by 0.6% per year) since 1975, rates appear to have stabilized over the past 5 data years. In contrast, death rates in individuals aged birth to 19 years have declined continuously, from 6.5 (per 100,000 population) in 1970 to 2.3 in 2015, an overall reduction of 65% (67% in children and 61% in adolescents). The 5-year relative survival rate for all cancers combined improved from 58% during the mid-1970s to 83% during 2007 through 2013 for children and from 68% to 84% for adolescents. However, survival varies substantially by cancer type and age at diagnosis (Table 14) .
Limitations
Although the estimated numbers of new cancer cases and deaths expected to occur in 2018 provide a reasonably accurate portrayal of the contemporary cancer burden, they are modelbased, 3-year-or 4-year-ahead projections that should be interpreted with caution and not be used to track trends over time. First, the estimates may be affected by changes in methodology as we take advantage of improvements in modeling techniques and cancer surveillance coverage. Second, although the models are robust, they can only account for trends through the most recent data year (currently 2014 for incidence and 2015 for mortality) and cannot anticipate abrupt fluctuations for cancers affected by changes in detection practice (eg, PSA testing and prostate cancer). Third, the model can be oversensitive to sudden or large changes in observed data. The most informative metrics for tracking cancer trends are age-standardized or agespecific cancer death rates from the NCHS and cancer incidence rates from SEER, NPCR, and/or NAACCR.
Errors in reporting race/ethnicity in medical records and on death certificates may result in underestimates of cancer incidence and mortality rates in nonwhite and nonblack populations. This is particularly relevant for American Indian/Alaska Native populations. It is also important to note that cancer data in the United States are primarily reported for broad, heterogeneous racial and ethnic groups, masking substantial and important differences in the cancer burden within these subpopulations. For example, although Hispanics in the United States have the lowest lung cancer mortality overall (one-half that in NHWs), within this population, rates in Cuban men approach those of NHW men. 79 Similarly, lung cancer rates are equivalent in Hawaiian and NHW men, but about 50% lower in Asian/Pacific Islanders overall. 63 Thus, the high burden of lung and other cancers among Cuban Americans and Hawaiians is completely concealed by the presentation of aggregated data.
Conclusions
The continuous decline in cancer death rates over 2 decades has resulted in an overall drop of 26%, resulting in approximately 2.4 million fewer cancer deaths during this time period. While the racial gap in cancer mortality continues to narrow, this progress primarily reflects older age groups, masking stark persistent inequalities for young and middleaged black Americans. High cancer mortality in Kentucky and West Virginia, irrespective of race, highlights the strong influence of socioeconomic and health policy factors on the cancer burden. Nevertheless, the elimination of racial disparities in many states, let alone lower cancer mortality in blacks in Massachusetts and New York, demonstrates the potential for the nation. Advancing the fight against cancer for all citizens requires broader application of existing cancer control knowledge, including smoking cessation and the increased uptake of cancer-preventing cervical and colorectal cancer screening and HPV vaccination, across all segments of the population, with an emphasis on disadvantaged groups.
